ANI Pharmaceuticals and Sofgen announced that the Food and Drug Administration (FDA) has approved Nimodipine Capsules.
Nimodipine is a calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (ie, Hunt and Hess Grades I–IV). Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle.
RELATED: Low Doses of CO May Lessen Brain Damage Post-Hemorrhage
Nimodipine Capsules will be available in a 30mg strength later this year.
For more information call or visit AniPharmaceuticals.com.